US 12,186,361 B2
Method and formulation for inhalation
Michelle McIntosh, Parkville (AU); David Morton, Parkville (AU); Tomas Sou, Parkville (AU); Livesey Olerile, Parkville (AU); and Richard Prankerd, Parkville (AU)
Assigned to Monash University, Clayton (AU)
Filed by Monash University, Clayton (AU)
Filed on Jun. 15, 2021, as Appl. No. 17/348,023.
Application 17/348,023 is a continuation of application No. 15/343,408, filed on Nov. 4, 2016, granted, now 11,065,297.
Application 15/343,408 is a continuation of application No. 14/236,465, abandoned, previously published as PCT/AU2011/001430, filed on Nov. 7, 2011.
Claims priority of application No. 2011903049 (AU), filed on Aug. 1, 2011.
Prior Publication US 2022/0152145 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 38/095 (2019.01); C07K 7/16 (2006.01)
CPC A61K 38/095 (2019.01) [A61K 9/0073 (2013.01); A61K 9/0075 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); C07K 7/16 (2013.01)] 13 Claims
 
1. An inhalable dry powder comprising spray dried particles, the particles comprising:
about 200 IU of oxytocin;
L-leucine in an amount of 10 to 40% by dry weight of said spray dried particles excluding the weight of oxytocin;
the weight remainder of said spray dried particles being an amorphous glass matrix consisting essentially of trehalose; and
wherein the oxytocin is dispersed within the amorphous glass matrix.